|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Soroka University Medical Center |
| Information provided by: | Soroka University Medical Center |
| ClinicalTrials.gov Identifier: | NCT00288769 |
Purpose
Background:
Recurrent aphthous stomatitis is a common phenomenon in Primary Medicine.Frequency of the phenomenon can be as high as 25% of the general population and the recurrence of the problem can be up to 50%.Different approaches for treatment are described: treatment with various natural vitamins , local ointments , disinfectant agents for local treatment , local antibiotic ointments , NSAID, local cortisone-steroids , and even medication on the basis of immune-depressants of the immune system and systematic steroids .
Methods:
A double-blind study of daily administration of sublingual Vitamin B12 tablets manufactured by Solgar (each tablet containing 1000 mcg. of Vitamin B12) opposed to placebo tablets.
Purpose of the research:
To investigate the effect of Vitamin B12 on the frequency of recurrent canker sores of the mouth (RAS).
Study hypothesis:
Treatment with vitamin B12 will reduce the recurrency rate and will diminish the symptomatology of RAS episodes.
| Condition | Intervention |
|
Recurrent Aphthous Stomatitis |
Drug: daily sublingual tablets Vitamin B12 1000 mcg versus placebo |
| ChemIDplus related topics: | Vitamin B 12 Hydroxocobalamin |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
| Study Start Date: | March 2006 |
| Estimated Study Completion Date: | December 2007 |
![]() |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 65 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | SOR415705CTIL |
| First Received: | February 7, 2006 |
| Last Updated: | August 6, 2007 |
| ClinicalTrials.gov Identifier: | NCT00288769 |
| Health Authority: | Israel: Ministry of Health |
|
|
|
|
|